Asian Spectator

Men's Weekly

.

Trio of 8½ Otto e Mezzo BOMBANA Chefs Present a Six-Michelin-Star Culinary Extravaganza at Galaxy Macau

Legendary Italian chef Umberto Bombana joins forces with the Executive Chefs of his Macau and Shanghai restaurants to celebrate the season of Australian Black Truffle and award-winning wine list at 8&...

Senheng Powers Up Malaysia with Solar Solutions Nationwide

Enjoy 10% S-Coin Cashback at all Senheng and senQ outletsSETIA ALAM MALAYSIA - Media OutReach Newswire - 16 December 2024 - Senheng is excited to announce the launch of its nationwide solar...

Gaw Capital Partners and Patience Capital Group Complete Acquisition of an Iconic Mall in Central Ginza, Tokyo

TOKYO, JAPAN - Media OutReach Newswire - 7 February 2025 - Real estate private equity firm Gaw Capital Partners today announced that the firm, through a fund under its management and invest...

New Data Presented at ACTRIMS Forum 2021 Indicate MAVENCLAD®-t...

DARMSTADT, Germany, Feb. 26, 2021 /PRNewswire-AsiaNet / -- MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following season...

Gamuda Land Adopts Yardi Elevate for Leasing and Deal Management

KUALA LUMPUR, Malaysia, Feb. 21, 2020 /PRNewswire-AsiaNet/-- Strengthening leasing and deal management with an easy-to-use, mobile-friendly solutionMalaysian property developer Gamuda Land w...

Unleash Culinary Creativity with Precision and Convenience: Samsung Expands Line-up of Built-in Kitchen Appliances in Singapore

Providing homeowners with more options to elevate their cooking experience with a wider range of Samsung Built-in Ovens, Induction Hobs and HoodsSINGAPORE - Media OutReach Newswire - 8 Janu...

Afton Chemical Wins Two "Top 5 Best Supplier" Awards at the 2n...

SINGAPORE, Dec. 20, 2018/PRNewswire-AsiaNet/-- Afton Chemical received the "Top 5 Best Fuel Additive Supplier" and"Top 5 Best Lubricant Supplier" awards at the 2nd Global Automotive Powertra...

Henley Partners Discusses Sovereign Equity at Davos

LONDON, Jan. 24, 2020 /PRNewswire-AsiaNet/ -- Henley & Partners (https://www.henleyglobal.com/) was delighted to take part in a Davos panel discussion during this week’s World Econ...

It takes a community to raise trees: SM Foundation, Inc. and t...

PASAY CITY, Philippines, Oct. 21, 2022 /PRNewswire-AsiaNet/ -- There is wisdom that takes root in the old proverb, 'it takes a village to raise a child'.In the same vein, SM Foundation, Inc...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Cemas saat berulang tahun? Simak tip psikolog untuk hadapi ‘birthday blues’

DavideAngelini/ShutterstockUlang tahun biasanya jadi momen membahagiakan penuh dengan tawa, perayaan, dan hadiah. Namun, tak jarang menjelang ulang tahun, kita justru merasa sedih.Ulang tahun dapat me...

Kenapa calon pengantin perlu cek kesehatan sebelum menikah?

● Cek kesehatan pranikah merupakan pemeriksaan kesehatan bagi calon pengantin.● Prosedur ini bisa cegah penularan infeksi seksual hingga penyakit keturunan.● Sejumlah daerah menjadik...

Militerisme di media sosial: Bagaimana UU TNI mengancam kebebasan sipil di dunia siber

Anggota Brigif Para Raiders, pasukan khusus TNI, sedang melakukan latihan tempur dalam rangka memperingati HUT TNI, pada 10 Oktober 2020 di Malang.Oyek Vizual Studio/Shutterstock● UU TNI baru me...